Susan McClatchey - Eterna Therapeutics VP Quality
| ERNA Stock | USD 0.29 0.03 9.38% |
Insider
Susan McClatchey is VP Quality of Eterna Therapeutics
| Address | 1035 Cambridge Street, Cambridge, MA, United States, 02141 |
| Phone | 212 582 1199 |
| Web | https://eternatx.com |
Eterna Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2942) % which means that it has lost $0.2942 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.5418) %, meaning that it created substantial loss on money invested by shareholders. Eterna Therapeutics' management efficiency ratios could be used to measure how well Eterna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 14, 2024, Return On Tangible Assets is expected to decline to -0.48. In addition to that, Return On Capital Employed is expected to decline to -0.52. At present, Eterna Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 41.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 114 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Ted Yednock | Annexon | 66 | |
| Stephen Elledge | Tscan Therapeutics | N/A | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Arnon Rosenthal | Annexon | 68 | |
| MD FAAAAI | Palisade Bio | N/A | |
| Joanne MD | Iteos Therapeutics | 52 | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| MSc MBA | Inozyme Pharma | 52 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Alexis AM | Relay Therapeutics | 52 | |
| JD MBA | Immix Biopharma | N/A | |
| Matthew Gall | Iteos Therapeutics | 47 | |
| Robert Dudley | Transcode Therapeutics | 73 | |
Management Performance
| Return On Equity | -11.54 | ||||
| Return On Asset | -0.29 |
Eterna Therapeutics Leadership Team
Elected by the shareholders, the Eterna Therapeutics' board of directors comprises two types of representatives: Eterna Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eterna. The board's role is to monitor Eterna Therapeutics' management team and ensure that shareholders' interests are well served. Eterna Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eterna Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Jackson, Chief Officer | ||
| Robert MD, Chief Officer | ||
| Susan McClatchey, VP Quality | ||
| Sandra Gurrola, Principal Finance | ||
| Megan Yung, Chief Officer | ||
| Sanjeev Luther, President CEO | ||
| Roger MD, Chief Officer | ||
| Matthew Angel, CEO Director | ||
| PharmD MBA, Chief Officer | ||
| Dorothy Clarke, General Director | ||
| Lynn MS, Ex Operations |
Eterna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eterna Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.54 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (104.91) % | ||||
| Current Valuation | 45.93 M | ||||
| Shares Outstanding | 51.37 M | ||||
| Shares Owned By Institutions | 10.99 % | ||||
| Number Of Shares Shorted | 115.02 K | ||||
| Price To Book | 2.10 X | ||||
| Price To Sales | 102.72 X | ||||
| Revenue | 68 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.